{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:50:27Z","timestamp":1793029827365,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA274640"],"award-info":[{"award-number":["R01 CA274640"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA254268"],"award-info":[{"award-number":["R01 CA254268"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA224605"],"award-info":[{"award-number":["R01 CA224605"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007911","name":"University of California San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["K12 GM068524"],"award-info":[{"award-number":["K12 GM068524"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.canlet.2025.218074","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:09:03Z","timestamp":1759518543000},"page":"218074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer"],"prefix":"10.1016","volume":"634","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7922-3773","authenticated-orcid":false,"given":"Debbie K.","family":"Ledezma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5220-5639","authenticated-orcid":false,"given":"Utsav","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Nguyen-Ta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2977-7636","authenticated-orcid":false,"given":"Himangshu","family":"Sonowal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9799-5985","authenticated-orcid":false,"given":"Hana","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel G.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole F.","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2185-8535","authenticated-orcid":false,"given":"Rebekah R.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.canlet.2025.218074_bib1","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.canlet.2025.218074_bib2","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (Anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2025.218074_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/293479","article-title":"The role of regulatory T cells and TH17 cells in multiple myeloma","volume":"2012","author":"Braga","year":"2012","journal-title":"Clin. Dev. Immunol."},{"issue":"9","key":"10.1016\/j.canlet.2025.218074_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2013.34","article-title":"Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg\/Th17 balance","volume":"3","author":"Bryant","year":"2013","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","article-title":"Dysfunctional T regulatory cells in multiple myeloma","volume":"107","author":"Prabhala","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2567.2009.03105.x","article-title":"Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma","volume":"128","author":"Zhao","year":"2009","journal-title":"Immunology"},{"issue":"9","key":"10.1016\/j.canlet.2025.218074_bib7","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00262-011-1178-0","article-title":"Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth","volume":"61","author":"Porembka","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.canlet.2025.218074_bib8","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1136\/gutjnl-2013-306271","article-title":"Targeted depletion of a MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity","volume":"63","author":"Stromnes","year":"2014","journal-title":"Gut"},{"issue":"6230","key":"10.1016\/j.canlet.2025.218074_bib9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science."},{"key":"10.1016\/j.canlet.2025.218074_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116492","article-title":"Overcoming therapy resistance in pancreatic cancer: new insights and future directions","volume":"229","author":"Espona-Fiedler","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218074_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","article-title":"Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy","volume":"262","author":"Martin","year":"2015","journal-title":"Ann. Surg."},{"issue":"2","key":"10.1016\/j.canlet.2025.218074_bib12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11605-017-3556-1","article-title":"Resection of locally advanced pancreatic cancer without regression of arterial encasement after modern-era neoadjuvant therapy","volume":"22","author":"Kluger","year":"2018","journal-title":"J. Gastrointest. Surg."},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jso.25110","article-title":"The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma","volume":"118","author":"Huang","year":"2018","journal-title":"J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.218074_bib14","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.jvir.2016.10.023","article-title":"Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma","volume":"28","author":"Narayanan","year":"2017","journal-title":"J. Vasc. Intervent. Radiol."},{"issue":"8","key":"10.1016\/j.canlet.2025.218074_bib15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.hpb.2018.12.004","article-title":"A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry","volume":"21","author":"Holland","year":"2019","journal-title":"HPB"},{"issue":"10","key":"10.1016\/j.canlet.2025.218074_bib16","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1158\/2326-6066.CIR-19-0101","article-title":"Irreversible electroporation combined with checkpoint blockade and TLR7 stimulation induces antitumor immunity in a murine pancreatic cancer model","volume":"7","author":"Narayanan","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","article-title":"Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.canlet.2025.218074_bib18","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1652532","article-title":"Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation","volume":"8","author":"Scheffer","year":"2019","journal-title":"OncoImmunology"},{"issue":"3","key":"10.1016\/j.canlet.2025.218074_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010222","article-title":"Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trial","volume":"13","author":"Geboers","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.canlet.2025.218074_bib20","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S2468-1253(24)00017-7","article-title":"MRI-guided stereotactic ablative body radiotherapy versus CT-guided percutaneous irreversible electroporation for locally advanced pancreatic cancer (CROSSFIRE): a single-centre, open-label, randomised phase 2 trial","volume":"9","author":"Timmer","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"9","key":"10.1016\/j.canlet.2025.218074_bib21","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1021\/acs.molpharmaceut.8b00316","article-title":"In situ vaccination with cowpea vs tobacco mosaic virus against melanoma","volume":"15","author":"Murray","year":"2018","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.canlet.2025.218074_bib22","article-title":"Cowpea mosaic virus promotes anti-tumor activity and immune memory in a mouse ovarian tumor model","volume":"2","author":"Wang","year":"2019","journal-title":"Adv. Ther."},{"issue":"21","key":"10.1016\/j.canlet.2025.218074_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00129-19","article-title":"Cowpea mosaic virus nanoparticles and empty virus-like particles show distinct but overlapping immunostimulatory properties","volume":"93","author":"Wang","year":"2019","journal-title":"J. Virol."},{"issue":"27","key":"10.1016\/j.canlet.2025.218074_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202002299","article-title":"A combination of cowpea mosaic virus and immune checkpoint therapy synergistically improves therapeutic efficacy in three tumor models","volume":"30","author":"Wang","year":"2020","journal-title":"Adv. Funct. Mater."},{"issue":"12","key":"10.1016\/j.canlet.2025.218074_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005834","article-title":"In situ vaccination with cowpea mosaic virus elicits systemic antitumor immunity and potentiates immune checkpoint blockade","volume":"10","author":"Mao","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2025.218074_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120914","article-title":"Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors","volume":"275","author":"Mao","year":"2021","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.canlet.2025.218074_bib27","doi-asserted-by":"crossref","first-page":"4878","DOI":"10.1039\/D4MA00427B","article-title":"Combination of cowpea mosaic virus (CPMV) intratumoral therapy and oxaliplatin chemotherapy","volume":"5","author":"Moreno-Gonzalez M","year":"2024","journal-title":"Mater. Adv."},{"issue":"11","key":"10.1016\/j.canlet.2025.218074_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007981","article-title":"Interaction of cowpea mosaic virus (CPMV) nanoparticles with antigen presenting cells in vitro and in vivo","volume":"4","author":"Gonzalez","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.218074_bib29","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41467-021-21858-1","article-title":"Tumor-penetrating therapy for \u03b25 integrin-rich pancreas cancer","volume":"12","author":"Hurtado de Mendoza","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib30","article-title":"Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model","volume":"11","author":"Narayanan","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2025.218074_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: a review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2025.218074_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217620","article-title":"Irreversible electroporation combined with PD-L1\/IL-6 dual blockade promotes anti-tumor immunity via cDC2\/CD4+T cell axis in MHC-I deficient pancreatic cancer","volume":"617","author":"Wu","year":"2025","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.canlet.2025.218074_bib33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.surg.2020.04.057","article-title":"A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma","volume":"168","author":"O'Neill","year":"2020","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.canlet.2025.218074_bib34","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jvir.2019.03.002","article-title":"Irreversible electroporation versus radiofrequency ablation: comparison of systemic immune responses in patients with hepatocellular carcinoma","volume":"30","author":"Sugimoto","year":"2019","journal-title":"J. Vasc. Intervent. Radiol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006133","article-title":"Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model","volume":"11","author":"Shankara Narayanan","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s44272-023-00005-5","article-title":"The role of innate immune cells as modulators of the tumor microenvironment in the metastasis and treatment of pancreatic cancer","volume":"2","author":"Zhu","year":"2023","journal-title":"CCB"},{"issue":"4","key":"10.1016\/j.canlet.2025.218074_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006221","article-title":"Irreversible electroporation augments \u03b2-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma","volume":"11","author":"Woeste","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"19","key":"10.1016\/j.canlet.2025.218074_bib38","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1039\/D0BM01219J","article-title":"The unique potency of cowpea mosaic virus (CPMV) in situ cancer vaccine","volume":"8","author":"Shukla","year":"2020","journal-title":"Biomater. Sci."},{"issue":"3","key":"10.1016\/j.canlet.2025.218074_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004044","article-title":"Neoadjuvant in situ vaccination with cowpea mosaic virus as a novel therapy against canine inflammatory mammary cancer","volume":"10","author":"Alonso-Miguel","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.canlet.2025.218074_bib40","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1021\/acs.molpharmaceut.8b00126","article-title":"Treatment of canine oral melanoma with nanotechnology-based immunotherapy and radiation","volume":"15","author":"Hoopes","year":"2018","journal-title":"Mol. Pharm."},{"issue":"5","key":"10.1016\/j.canlet.2025.218074_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154016","article-title":"Cytokines as biomarkers of pancreatic ductal adenocarcinoma: a systematic review","volume":"11","author":"Yako","year":"2016","journal-title":"PLoS One."},{"issue":"2B","key":"10.1016\/j.canlet.2025.218074_bib46","first-page":"1355","article-title":"Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients","volume":"21","author":"Karayiannakis","year":"2001","journal-title":"Anticancer. Res."},{"issue":"5","key":"10.1016\/j.canlet.2025.218074_bib47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s004230050233","article-title":"Tumor size and lymph-node status in pancreatic carcinoma - is there a correlation to the preoperative immune function?","volume":"384","author":"Wenger","year":"1999","journal-title":"Langenbecks Arch. Surg."},{"issue":"22","key":"10.1016\/j.canlet.2025.218074_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153242","article-title":"Targeting TNF-\u03b1\u2013producing macrophages activates antitumor immunity in pancreatic cancer via IL-33 signaling","volume":"7","author":"Dixit","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.canlet.2025.218074_bib49","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1083\/jcb.201301001","article-title":"Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-\u03baB and MMPs","volume":"202","author":"Liou","year":"2013","journal-title":"JCB (J. Cell Biol.)"},{"issue":"6","key":"10.1016\/j.canlet.2025.218074_bib50","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ccr.2012.04.025","article-title":"Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer","volume":"21","author":"Bayne","year":"2012","journal-title":"Cancer Cell."},{"key":"10.1016\/j.canlet.2025.218074_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1352821","article-title":"Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model","volume":"15","author":"Imran","year":"2024","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.canlet.2025.218074_bib41","doi-asserted-by":"crossref","first-page":"18315","DOI":"10.1021\/acsnano.2c06143","article-title":"In vivo fate of cowpea mosaic virus in situ vaccine: biodistribution and clearance","volume":"16","author":"Affonso de Oliveira","year":"2022","journal-title":"ACS Nano."},{"issue":"1\u20132","key":"10.1016\/j.canlet.2025.218074_bib42","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2007.04.003","article-title":"Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo","volume":"120","author":"Singh","year":"2007","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/vaccines13010040","article-title":"Immunotherapeutic potential of the yellow fever virus vaccine strain 17D for intratumoral therapy in a murine model of pancreatic cancer","volume":"13","author":"Nazarenko","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.canlet.2025.218074_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1546242","article-title":"Enhancing pancreatic cancer treatment: the role of H101 oncolytic virus in irreversible electroporation","volume":"16","author":"Xi","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-024-06982-0","article-title":"Cellular fate of a plant virus immunotherapy candidate","volume":"7","author":"Omole","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2025.218074_bib55","article-title":"Preclinical SC and IV repeat-dose toxicology of a cowpea mosaic virus \u2013 a cancer immunotherapy candidate","volume":"14","author":"Stern","year":"2025","journal-title":"Toxicol. Rep."},{"issue":"7","key":"10.1016\/j.canlet.2025.218074_bib56","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.jvir.2023.03.016","article-title":"Treatment of hepatocellular carcinoma by multimodel in situ vaccination using cryoablation and a plant virus immunostimulant","volume":"34","author":"Ghani","year":"2023","journal-title":"J Vasc. Interv. Radiol."},{"key":"10.1016\/j.canlet.2025.218074_bib57","author":"White"},{"issue":"1","key":"10.1016\/j.canlet.2025.218074_bib59","first-page":"165","article-title":"Perioperative systemic immunophenotype following irreversible electroporation (IRE) predicts recurrence","volume":"12","author":"O'Neill","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"15","key":"10.1016\/j.canlet.2025.218074_bib60","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.3390\/cancers13153902","article-title":"Irreversible electroporation and nivolumab combined with intratumoral administration of a toll-like receptor ligand, as a means of in vivo vaccination for metastatic pancreatic ductal adenocarcinoma (PANFIRE-III). A Phase-I Study protocol","volume":"13","author":"Geboers","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.canlet.2025.218074_bib61","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1021\/bm301278f","article-title":"Interior engineering of a viral nanoparticle and its tumor homing properties","volume":"13","author":"Wen","year":"2012","journal-title":"Biomacromolecules"},{"issue":"6","key":"10.1016\/j.canlet.2025.218074_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10693","article-title":"Cowpea mosaic virus intratumoral immunotherapy maintains stability and efficacy after long\u2010term storage","volume":"9","author":"Simms","year":"2024","journal-title":"Bioeng Transl Med"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525006469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525006469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T21:19:22Z","timestamp":1785273562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525006469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":59,"alternative-id":["S0304383525006469"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218074","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.218074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218074"}}